WO2022188729 - FUSED RING DERIVATIVES USEFUL AS KRAS G12D INHIBITORS
National phase entry:
Publication Number
WO/2022/188729
Publication Date
15.09.2022
International Application No.
PCT/CN2022/079476
International Filing Date
07.03.2022
Title **
[English]
FUSED RING DERIVATIVES USEFUL AS KRAS G12D INHIBITORS
[French]
DÉRIVÉS CYCLIQUES FUSIONNÉS UTILES EN TANT QU'INHIBITEURS DE KRAS G12D
Applicants **
JACOBIO PHARMACEUTICALS CO., LTD.
Building 8, No.105, Jinghai 3rd Road, Business Development Area
Tongzhou District, Beijing 100176, CN
Inventors
HAN, Huifeng
Building 8, No.105, Jinghai 3rd Road, Business Development Area
Tongzhou District, Beijing 100176, CN
GAO, Panliang
Building 8, No.105, Jinghai 3rd Road, Business Development Area
Tongzhou District, Beijing 100176, CN
MA, Cunbo
Building 8, No.105, Jinghai 3rd Road, Business Development Area
Tongzhou District, Beijing 100176, CN
WANG, Peng
Building 8, No.105, Jinghai 3rd Road, Business Development Area
Tongzhou District, Beijing 100176, CN
LONG, Wei
Building 8, No.105, Jinghai 3rd Road, Business Development Area
Tongzhou District, Beijing 100176, CN
ZHANG, Hao
Building 8, No.105, Jinghai 3rd Road, Business Development Area
Tongzhou District, Beijing 100176, CN
ZHANG, Lei
Building 8, No.105, Jinghai 3rd Road, Business Development Area
Tongzhou District, Beijing 100176, CN
LIU, Dan
Building 8, No.105, Jinghai 3rd Road, Business Development Area
Tongzhou District, Beijing 100176, CN
Priority Data
PCT/CN2021/079457
07.03.2021
CN
PCT/CN2021/100923
18.06.2021
CN
PCT/CN2021/120980
27.09.2021
CN
PCT/CN2022/071298
11.01.2022
CN
PCT/CN2022/073228
21.01.2022
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2284 | |
| EPO | Filing, Examination | 13692 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 703 | |
| USA | Filing, Examination | 6710 |
Total: 23976 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The disclosure relates to a KRAS G12D inhibitors of formula (I) or formula (IV), a composition containing the inhibitor and the use thereof.[French]
L'invention concerne des inhibiteurs de KRAS G12D de formule (I) ou de formule (IV), une composition contenant l'inhibiteur et leur utilisation.